ECHELON-2 (NCT01777152), A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN plus CHP VS CHOP IN PREVIOUSLY UNTREATED PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA: 5-YEAR RESULTSP. L. Zinzani,T. Illidge,S. M. Horwitz,O. A. O'Connor,B. Pro,S. P. Iyer,R. Advani,N. L. Bartlett,J. H. Christensen,F. Morschhauser,E. Domingo-Domenech,G. Rossi, W. S. Kim,T. A. Feldman,T. Menne,D. Belada,A. Illes,K. Tobinai,K. Tsukasaki,S-P. Yeh,A. Huttmann,K. J. Savage,S. Yuen,H. Miao,V. Bunn,K. Fenton,M. A. Fanale,M. Puhlmann,L. TrumperHAEMATOLOGICA（2021）引用 0|浏览25暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
